Regulating diagnosis in post-genomic medicine: Re-aligning clinical judgment?

Social Science and Medicine

Volumn 73, Issue 6, 2011, Pages 816-824

  Bourret, Pascale ^a   Keating, Peter ^b   Cambrosio, Alberto ^c  

^a AIX MARSEILLE UNIV   (France)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Clinical judgment; Diagnosis; FDA; Gene expression profiling; IVDMIA; Prediction; Prognosis; Regulation; Tumor signature

Indexed keywords

CANCER; DECISION MAKING; DISEASE TREATMENT; GENOMICS; MEDICAL GEOGRAPHY; TECHNOLOGICAL DEVELOPMENT;

ARTICLE; BREAST CANCER; CANCER GENETICS; CLINICAL DECISION MAKING; EARLY DIAGNOSIS; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCUS; GENE TECHNOLOGY; GENETIC RISK; GENOME ANALYSIS; GOVERNMENT REGULATION; HUMAN; MOLECULAR DIAGNOSIS; PRACTICE GUIDELINE; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

UNITED STATES;

EID: 80052265034     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2011.04.022     Document Type: Article

References (34)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Berg M. The construction of medical disposals, medical sociology and medical problem solving in clinical practice. Sociology of Health and Illness 1992, 14:151-180.
3. Boltanski L., Thévenot L. The sociology of critical capacity. European Journal of Social Theory 1999, 2:359-477.
4. Boltanski L., Thévenot L. On justification: Economies of worth 2006, Princeton University Press, Princeton, NJ.
5. Bourret P. BRCA patients and clinical collectives: new configurations of action in cancer genetics practices. Social Studies of Science 2005, 35:41-68.
6. Callon M. Some elements of a sociology of translation: the domestication of the scallops and the fishermen of Saint Brieuc Bay. Power, action and belief: A new sociology of knowledge? 1986, 196-229. Routledge & Kegan Paul, London. J. Law (Ed.).
7. Callon M., Rabeharisoa V. The growing engagement of emergent concerned groups in political and economic life: lessons from the French association of neuromuscular disease patients. Science, Technology & Human Values 2008, 33:230-261.
8. Cambrosio A., Keating P., Schlich T., Weisz G. Regulatory objectivity and the generation and management of evidence in medicine. Social Science & Medicine 2006, 63:189-199.
9. College of American Pathologists Technology Assessment Committee, in vitro diagnostic multivariate index assays (IVDMIA) 2009, CAP, available at. http://www.cap.org/apps/docs/committees/technology/ivdmia.pdf.
10. Christakis N. Death foretold: Prophecy and prognosis in medical care 1999, University of Chicago Press, Chicago, IL.
11. Evans B.J. What will it take to reap the clinical benefits of pharmacogenomics?. Food and Drug Law Journal 2006, 61:753-794.
12. Fong T. Agendia Planning to File IPO in 2011 Genome web 2011, January 14; available at. http://www.genomeweb.com/print/959748?hq_e=el%26hq_m=908479%26hq_l=1%26hq_v=c4e8b2429.
13. Garber K. Ready or not: personal tumor profiling tests take off. The Journal of the National Cancer Institute 2011, 103:84-86.
14. Gibbs, J. N. (2007). ASRs and IVDMIAs: FDA's new draft guidances. Two new draft guidances could affect how laboratory tests are developed in the future. IVD Technology. available at. http://www.devicelink.com/ivdt/archive/07/03/012.html.
15. Hartland J. The use of " intelligent" machines for electrocardiograph interpretation. Technology in working order: Studies of work, interaction, and technology 1993, 55-80. Routledge, London. G. Button (Ed.).
16. Jutel A. Sociology of diagnosis: a preliminary review. Sociology of Health & Illness 2009, 31:278-299.
17. Keating P., Cambrosio A. Biomedical platforms. Realigning the normal and the pathological in late-twentieth-century medicine 2003, MIT Press, Cambridge, MA.
18. Keating P., Cambrosio A. Does biomedicine entail the successful reduction of pathology to biology?. Perspectives in Biology and Medicine 2004, 47:357-371.
19. Knaapen L., Cazeneuve H., Cambrosio A., Castel P., Fervers B. Pragmatic evidence and textual arrangements: a case study of French clinical cancer guidelines. Social Science & Medicine 2010, 71:685-692.
20. Kohli-Laven, N., Bourret, P., Keating, P., & Cambrosio, A. Cancer clinical trials in the era of genomic signatures: biomedical innovation, clinical utility, and regulatory-scientific hybrids. Social Studies of Science, in press; doi:10.1177/0306312711398741.
21. Lakhman, K. (2006). OIVD wants to discuss Oncotype Dx's status with genomic health; more insight into FDA's IVD goal? Pharmacogenomics Reporter. available at. (February 1). http://www.genomeweb.com/print/672820.
22. Latour B. Reassembling the social: An introduction to actor-network-theory 2005, Oxford University Press, Oxford.
23. Mol A. The body multiple. Ontology in medical practice 2002, Duke University Press, Durham.
24. Moreira T. Diversity in clinical guidelines: the role of repertoires of evaluation. Social Science & Medicine 2005, 60:1975-1985.
25. Nachi M. Introduction à la sociologie pragmatique 2006, Armand Colin, Paris.
26. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
27. Ploem M.C., Retèl V.P., Linn S.C., van Boven H.H., Schmidt M.K., et al. Tumour tissue: who is in control?. Lancet Oncology 2010, 11:9-11.
28. Q&A: FDA's Zineh reviews 2010 personalized Rx efforts and discusses future plans (2011), Genome web 2010, Q&A: FDA's Zineh reviews, January 5, available at. http://www.genomeweb.com/print/958917?hq_e=el%26hq_m=903163%26hq_l=1%26hq_v=c4e8b24249.
29. Rabeharisoa V., Bourret P. Staging and weighting evidence in biomedicine: comparing clinical practices in cancer genetics and psychiatric genetics. Social Studies of Science 2009, 39:691-715.
30. Reis-Filho J.S., Westbury C., Pierga J.-Y. The impact of expression profiling on prognostic and predictive testing in breast cancer. Journal of Clinical Pathology 2006, 59:225-231.
31. Shiang C., Pusztai L. Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics. Breast Cancer Research 2010, 12(Suppl 4):S6.
32. Taube S.E., Clark G.M., Dancey J.E., McShane L.M., Sigman C.S., Gutman S.I. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. The Journal of the National Cancer Institute 2009, 101:1453-1463.
33. Weigelt B., Reis-Filho J.S. Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Research 2010, 12(Suppl 4):S5.
34. Woodcock J. The prospects for " personalized medicine" in drug development and drug therapy. Clinical Pharmacology and Therapeutics 2007, 81:164-169.